دورية أكاديمية
أعرض في EDS

Drug-susceptible tuberculosis treatment success and associated factors in Ethiopia from 2005 to 2017: a systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Drug-susceptible tuberculosis treatment success and associated factors in Ethiopia from 2005 to 2017: a systematic review and meta-analysis.
المؤلفون: Seid MA; Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia., Ayalew MB; Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia., Muche EA, Gebreyohannes EA; Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia., Abegaz TM; Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia.
المصدر: BMJ open [BMJ Open] 2018 Sep 25; Vol. 8 (9), pp. e022111. Date of Electronic Publication: 2018 Sep 25.
نوع المنشور: Journal Article; Meta-Analysis; Systematic Review
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
مواضيع طبية MeSH: Antitubercular Agents/*therapeutic use , HIV Infections/*complications , Tuberculosis, Pulmonary/*drug therapy, Age Factors ; Coinfection/complications ; Ethiopia ; Humans ; Observational Studies as Topic ; Rural Population ; Treatment Failure ; Tuberculosis, Pulmonary/complications
مستخلص: Objectives: The main aim of this study was to assess the overall tuberculosis (TB) treatment success in Ethiopia and to identify potential factors for poor TB treatment outcome.
Design: A systematic review and meta-analysis of published literature was conducted. Original studies were identified through a computerised systematic search using PubMed, Google Scholar and Science Direct databases. Heterogeneity across studies was assessed using Cochran's Q test and I 2 statistic. Pooled estimates of treatment success were computed using the random-effects model with 95% CI using Stata V.14 software.
Results: A total of 230 articles were identified in the systematic search. Of these 34 observational studies were eligible for systematic review and meta-analysis. It was found that 117 750 patients reported treatment outcomes. Treatment outcomes were assessed by World Health Organization (WHO) standard definitions of TB treatment outcome. The overall pooled TB treatment success rate in Ethiopia was 86% (with 95% CI 83%_88%). TB treatment success rate for each region showed that, Addis Ababa (93%), Oromia (84%), Amhara (86%), Southern Nations (83%), Tigray (85%) and Afar (86%). Mainly old age, HIV co-infection, retreatment cases and rural residence were the most frequently identified factors associated with poor TB treatment outcome.
Conclusion: The result of this study revealed that the overall TB treatment success rate in Ethiopia was below the threshold suggested by WHO (90%). There was also a discrepancy in TB treatment success rate among different regions of Ethiopia. In addition to these, HIV co-infection, older age, retreatment cases and rural residence were associated with poor treatment outcome. In order to further improve the treatment success rate, it is strategic to give special consideration for regions which had low TB treatment success and patients with TB with HIV co-infection, older age, rural residence and retreatment cases.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: Public Health Action. 2014 Dec 21;4(Suppl 3):S13-7. (PMID: 26478507)
PLoS One. 2016 Jul 21;11(7):e0159579. (PMID: 27442529)
BMC Public Health. 2013 Feb 19;13:154. (PMID: 23421987)
Braz J Infect Dis. 2013 Sep-Oct;17(5):521-8. (PMID: 23830051)
PLoS One. 2015 Dec 15;10(12):e0144244. (PMID: 26669737)
J Infect Dev Ctries. 2015 Jul 30;9(7):752-9. (PMID: 26230126)
Lancet. 2010 Jun 12;375(9731):2100-9. (PMID: 20488518)
Ethiop J Health Sci. 2016 Jan;26(1):65-72. (PMID: 26949318)
Int J Tuberc Lung Dis. 2010 Aug;14(8):973-9. (PMID: 20626941)
BMC Res Notes. 2015 Sep 29;8:503. (PMID: 26420164)
BMC Infect Dis. 2016 Nov 4;16(1):640. (PMID: 27814693)
Tuberc Res Treat. 2014;2014:726193. (PMID: 24891948)
PLoS One. 2016 Feb 26;11(2):e0150560. (PMID: 26918458)
BMC Public Health. 2016 Jul 21;16:612. (PMID: 27443308)
J Infect Dis. 2017 Nov 3;216(suppl_6):S629-S635. (PMID: 29112747)
BMC Infect Dis. 2016 Nov 8;16(1):653. (PMID: 27825309)
Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. (PMID: 28256383)
Braz J Infect Dis. 2016 Nov - Dec;20(6):635-636. (PMID: 27553661)
Indian J Tuberc. 2017 Oct;64(4):252-275. (PMID: 28941848)
BMC Public Health. 2015 Jan 21;15:15. (PMID: 25605404)
Pan Afr Med J. 2015 Mar 16;20:247. (PMID: 26161170)
BMC Public Health. 2012 Jul 23;12:537. (PMID: 22824524)
Glob Health Action. 2014 Sep 19;7:25382. (PMID: 25242174)
Tuberc Res Treat. 2016;2016:1294876. (PMID: 27313887)
Psychol Methods. 2006 Jun;11(2):193-206. (PMID: 16784338)
Tuberc Res Treat. 2016;2016:1354356. (PMID: 27597896)
Afr Health Sci. 2016 Sep;16(3):663-670. (PMID: 27917197)
BMC Infect Dis. 2017 Feb 8;17(1):132. (PMID: 28178936)
J Infect Dev Ctries. 2015 Aug 29;9(8):821-8. (PMID: 26322873)
PLoS One. 2015 Jun 15;10(6):e0128907. (PMID: 26075615)
Bull World Health Organ. 2007 May;85(5):377-81; discussion 382-6. (PMID: 17639223)
Scand J Infect Dis. 2009;41(6-7):450-5. (PMID: 20001277)
J Int Assoc Provid AIDS Care. 2015 Nov-Dec;14(6):560-70. (PMID: 26289343)
Infect Dis Poverty. 2016 Mar 21;5:22. (PMID: 27009088)
PLoS One. 2015 Nov 09;10(11):e0142290. (PMID: 26551023)
N Engl J Med. 2012 Sep 6;367(10):931-6. (PMID: 22931261)
BMC Public Health. 2009 Oct 04;9:371. (PMID: 19799801)
BMC Public Health. 2016 Aug 02;16:688. (PMID: 27485507)
BMJ Glob Health. 2017 Jul 28;2(2):e000318. (PMID: 29081999)
BMC Public Health. 2007 Oct 14;7:291. (PMID: 17935630)
Pan Afr Med J. 2017 Nov 02;28:197. (PMID: 29610635)
PLoS One. 2016 Apr 20;11(4):e0153239. (PMID: 27096159)
PLoS One. 2014 Dec 02;9(12):e114225. (PMID: 25460363)
Braz J Infect Dis. 2015 Jan-Feb;19(1):47-51. (PMID: 25467923)
BMC Public Health. 2005 Jun 06;5:62. (PMID: 15938746)
BMJ Glob Health. 2017 Nov 2;2(4):e000390. (PMID: 29209537)
PLoS One. 2018 Mar 19;13(3):e0194675. (PMID: 29554144)
BMC Infect Dis. 2014 Jul 02;14:360. (PMID: 24990578)
MMWR Morb Mortal Wkly Rep. 2006 Mar 24;55(11):301-5. (PMID: 16557213)
BMC Pediatr. 2014 Mar 03;14:61. (PMID: 24581267)
BMC Res Notes. 2015 Nov 11;8:666. (PMID: 26559922)
Glob Health Action. 2015 Mar 27;8:27048. (PMID: 25819037)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
فهرسة مساهمة: Keywords: drug-susceptible; ethiopia; meta-analysis; systematic review; treatment outcome; tuberclosis
المشرفين على المادة: 0 (Antitubercular Agents)
تواريخ الأحداث: Date Created: 20180928 Date Completed: 20191025 Latest Revision: 20191025
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6169771
DOI: 10.1136/bmjopen-2018-022111
PMID: 30257846
قاعدة البيانات: MEDLINE
الوصف
تدمد:2044-6055
DOI:10.1136/bmjopen-2018-022111